Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600381's Return-on-Tangible-Equity is ranked worse than 77.98% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.95
vs SHSE:600381: -6.59
Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Qinghai Spring Medicinal Resources Technology Co Return-on-Tangible-Equity Related Terms
Qinghai Spring Medicinal Resources Technology Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qinghai Spring Medicinal Resources Technology Co Return-on-Tangible-Equity Chart
Qinghai Spring Medicinal Resources Technology Co Annual Data
SHSE:600381 vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Qinghai Spring Medicinal Resources Technology Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qinghai Spring Medicinal Resources Technology Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -7.02% mean?
Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) has a Return-on-Tangible-Equity of -7.02% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Qinghai Spring Medicinal Resources Technology Co and its competitors. According to the industry distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #701 out of 899 companies in the Drug Manufacturers industry, placing it in the top 78%.
Is Qinghai Spring Medicinal Resources Technology Co's Return-on-Tangible-Equity too high?
Qinghai Spring Medicinal Resources Technology Co's current Return-on-Tangible-Equity is -7.02%. Based on the distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #701 out of 899 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Qinghai Spring Medicinal Resources Technology Co has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qinghai Spring Medicinal Resources Technology Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #701 out of 899 companies for Return-on-Tangible-Equity. This places Qinghai Spring Medicinal Resources Technology Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.95, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Qinghai Spring Medicinal Resources Technology Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qinghai Spring Medicinal Resources Technology Co's current Return-on-Tangible-Equity is -7.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qinghai Spring Medicinal Resources Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥5.85, compared to a current price of ¥3.80 — trading 35% below its estimated fair value. The current Return-on-Tangible-Equity is -7.02%. Qinghai Spring Medicinal Resources Technology Co's overall GF Score™ is 64/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Qinghai Spring Medicinal Resources Technology Co (SHSE:600381), the current Return-on-Tangible-Equity is -7.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) Overvalued in 2026?
Based on GuruFocus' analysis, Qinghai Spring Medicinal Resources Technology Co stock appears to be undervalued.
The current stock price of ¥3.80 is trading 35% below its estimated GF Value™ of ¥5.85.
GuruFocus considers Qinghai Spring Medicinal Resources Technology Co to be Significantly Undervalued.
Key valuation signals for SHSE:600381:
Return-on-Tangible-Equity: -7.02%
GF Value™: ¥5.85 vs. price of ¥3.80 (35% below fair value)
No single metric tells the full story. See the SHSE:600381 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qinghai Spring Medicinal Resources Technology Co Business Description
Qinghai Spring Medicinal Resources Technology Co Ltd is a China-based company that principally engaged in the integrated development, utilization, production, sales, and consulting services of the natural advantageous resources on the Qinghai-Tibet plateau, as well as the development and utilization of other biological resources. The Company's main products are the cordyceps sinensis series products under the Verygrass brand, which includes cordyceps sinensis pure powder tablet, processed cordyceps sinensis, and raw cordyceps sinensis.
64GF Score
Get the complete analysis for SHSE:600381
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600381 has been successfully added to your 
